Early Detection Research Network


This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.
A CART analysis fashioned from these six analytes was used to define a specific algorithm for classifying patients according to NSCLC disease status. This algorithm provided excellent ROC parameters for the overall study, including an AUC of 0.964, a sensitivity of 94.8%, and a specificity of 91.1%. The overall misclassification rate was 7% against the entire patient population (n = 196). The general agreement of the results yielded by the two multivariate algorithms (i.e., random forest and CART) serves as an ad hoc ÃÆ'¢â‚¬Åâ€Å"internal confirmationÃÆ'¢â‚¬Â for the specific six analytes selected by each method and generates confidence in our methods.

There are currently no items in this folder.